Overexpression of SPRY2 abolishes the inhibitory effect of co-inhibition of FGFR, EGFR, and MET on tumor growth despite reduced ERK and Akt activation, suggesting that additional mechanisms are involved in the tumorigenic potential of SPRY2 in GB [20]. The gene discussed is EGFR; the disease is neoplasm.